Feed SLP
SL

Simulations Plus, Inc.

SLP · NASDAQ

$18.42 -0.22% (-$0.04)
1M +0.60%
Market Cap $372.5M
P/E Ratio 45.96x
Div. Yield -
ROE 6.18%

Bulios Fair Price

$13.27

28.0% downside

Current Price

$18.42

Undervalued Fair Value Overvalued

According to Bulios Fair Price, SLP is currently overvalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Strong
7/9
Valuation
76 /100
Cheap
EV/EBITDA 25.81x
P/S 4.54x
P/B 2.68x
Growth
43 /100
Stable
FCF growth 7.72%
Book val. growth 11.20%
Rev. growth 13.67%
Profitability
71 /100
Strong
Net margin 9.88%
Op. margin 14.02%
FCF margin 31.78%
Quality
31 /100
Poor
ROE 6.18%
ROA 5.30%
Asset turnover 0.54x
Debt
100 /100
Low
Current ratio 5.54x
Net debt/EBITDA -2.66x
Debt/Equity 0.00x
Stability
49 /100
Moderate
Rev. volatility 3.54%
EPS volatility 431.94%
Profitable years 0

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about SLP
Online

About the company

Simulations Plus is an American company focused on the development and provision of software solutions in the pharmaceutical and biotechnology research field. The company's main headquarters is located in Lancaster, California. Simulations Plus specializes in developing models and simulations for pharmacokinetics, pharmacodynamics, and other aspects of drug research.

Sector

Technology

Industry

Software - Application

CEO

Shawn O'Connor

Employees

213

Headquarters

Research Triangle Park

Upcoming events

29 OCT

Earnings

Upcoming earnings report

47d
07 DEC

Earnings

Upcoming earnings report

86d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.